首页> 外文期刊>Journal of Cachexia, Sarcopenia and Muscle >Relationship between pancreatic cancer‐associated diabetes and cachexia
【24h】

Relationship between pancreatic cancer‐associated diabetes and cachexia

机译:胰腺癌相关糖尿病与恶病的关系

获取原文
           

摘要

Background Pancreatic cancer‐associated diabetes mellitus (PCDM) is a paraneoplastic phenomenon characterized by worsening hyperglycaemia and weight loss. Galectin‐3 and S100A9, mediators of PCDM, have pro‐inflammatory functions and might thereby induce systemic inflammation and cachexia. We aimed to examine whether PCDM directly mediates cachexia. Methods Consecutive pancreatic cancer (PC) patients with and without PCDM (n?=?88 each) with complete information were included. Cachexia was defined as weight loss 5% within 6?months or weight loss 2% and body mass index 20?kg/m2 or sarcopenia. Skeletal muscle mass was measured with lumbar skeletal muscle index (SMI) using computed tomography images. Cachexia‐related parameters (prevalence of cachexia, weight loss, and SMI) were compared between patients with and without PCDM. Relations between cachexia‐related parameters and fasting blood glucose or serum levels of galectin‐3 and S100A9 were analysed by Spearman correlation and logistic regression analyses. Results One hundred two (58.0%) patients had cachexia at diagnosis. No significant differences existed between patients with and without PCDM in prevalence of cachexia (64.8% vs. 51.1%, P?=?0.093), percentage of weight loss (median 6.8 vs. 4.0, P?=?0.085), and SMI (median 45.8 vs. 45.3?cm2/m2 in men, P?=?0.119; 34.9 vs. 36.3?cm2/m2 in women, P?=?0.418). In patients with cachexia, the percentage of weight loss and SMI were also similar between patients with and without PCDM. In patients with PCDM, fasting blood glucose was comparable between patients with and without cachexia (P?=?0.458) and did not correlate with the percentage of weight loss (P?=?0.085) or SMI (P?=?0.797 in men and 0.679 in women). Serum S100A9 level correlated with fasting blood glucose (correlation coefficient 0.213, P?=?0.047) but not with the percentage of weight loss (P?=?0.977) or SMI (P?=?0.247 in men and 0.458 in women). Serum galectin‐3 level also did not correlate with the percentage of weight loss (P?=?0.226) and SMI (P?=?0.201 in men and 0.826 in women). Primary tumour size was associated with cachexia (adjusted odds ratio per 1?cm increase 1.28, 95% confidence interval 1.02–1.60, P?=?0.034), whereas PCDM, fasting blood glucose, and levels of galectin‐3 and S100A9 were not predictors of cachexia. Conclusions Neither fasting blood glucose nor levels of galectin‐3 and S100A9 were associated with cachexia‐related parameters. Mediators of PCDM and hyperglycaemia do not directly mediate PC‐induced cachexia.
机译:背景技术胰腺癌相关糖尿病Mellitus(PCDM)是一种使高血糖和体重减轻恶化的静脉塑料现象。 Galectin-3和S100A9,PCDM的介质,具有促炎功能,从而诱导全身炎症和恶病症。我们旨在检查PCDM是否直接调解恶酷疟疾。方法将胰腺癌(PC)连续胰腺癌(PC)患者无关,包括完整信息的PCDM(N?=?88)。恶病症定义为重量损失> 5%在6.个月或体重减轻> 2%和体重指数<20?kg / m2或sarcopenia。使用计算机断层摄影图像用腰部骨骼肌指数(SMI)测量骨骼肌肿块。在有和没有PCDM的患者之间比较了与患者的恶化相关的参数(恶毒症,体重减轻和SMI)。通过Spearman相关和Logistic回归分析分析了与CaChexia相关参数和空腹血糖或血清水平的关系的关系和血凝素-3和S100A9的关系。结果诊断百分之百(58.0%)患者在诊断中患有恶病质。患者之间没有显着的差异,没有PCDM患病率患病率(64.8%与51.1%,p?= 0.093),减肥百分比(中位数6.8与4.0,p?= 0.085),和SMI(中位数45.8与45.3?MEN,P?=?0.119; 34.9与36.3?女性,P?= 0.418)。在患者患者中,在没有PCDM的患者之间的体重减轻和SMI的百分比也相似。在PCDM的患者中,患有患者的血糖与没有恶病症的患者(p?= 0.458),并且与体重减轻的百分比没有相关(p?= 0.085)或smi(p?= 0.797和0.679人)。血清S100A9水平与空腹血糖相关(相关系数0.213,p?= 0.047),但不是重量损失的百分比(p?= 0.977)或smi(p?= 0.247在女性中的0.458岁)。血清Galectin-3水平也没有与体重减轻的百分比相关(P?= 0.226)和SMI(P?= 0.201在女性中的0.826)。原发性肿瘤大小与恶病毒有关(调节的每1μm,95%置信区间1.02-1.60,p?= 0.034),而PCDM,空腹血糖和Galectin-3和S100a9的水平没有恶毒教视的预测因素。结论既不与高凝集素-3和S100A9的空腹血糖也不是与恶病性相关的参数有关。 PCDM和高血糖症的介质不会直接介导PC诱导的恶病因。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号